Zulvac 1 Bovis
inactivated bluetongue virus, serotype 1
Table of contents
Overview
The marketing authorisation for Zulvac 1 Bovis has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Zulvac 1 Bovis
|
| Agency product number |
EMEA/V/C/002334
|
| Active substance |
inactivated bluetongue virus, serotype 1
|
| International non-proprietary name (INN) or common name |
inactivated bluetongue virus, serotype 1
|
| Species |
Cattle
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AA08
|
Accelerated assessment |
This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
05/08/2011
|
| Contact address |
Rue Laid Burniat 1 |
Product information
21/06/2019 Zulvac 1 Bovis - EMEA/V/C/002334 - IB/00017
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.
Onset of immunity: 15 days after completion of the primary vaccination course.
Duration of immunity: 12 months.